CRON
Cronos Group, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.25
+1.25%Year over year
Reported trailing growth
- Revenue
- +72.9%
- EBITDA
- +144.4%
- EBIT
- +123.2%
- EPS
- +214.2%
- Free cash flow
- +628.2%
- Operating cash flow
- +200.1%
Forward estimates
Based on analyst estimates
- Revenue
- +20.8%
- EBITDA
- +847.5%
- EPS
- +19.5%
Three-year CAGR
- Revenue
- +19.8%
- EBITDA
- +93.3%
- EBIT
- +76.7%
- Net income
- —
- EPS
- —
- Free cash flow
- -97.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026